<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117668">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01905969</url>
  </required_header>
  <id_info>
    <org_study_id>MIAST-NJBMR-12</org_study_id>
    <nct_id>NCT01905969</nct_id>
  </id_info>
  <brief_title>Predictive Biomarkers in Stage II/III Gastric Cancer for Adjuvant Chemotherapy</brief_title>
  <acronym>NJBMR</acronym>
  <official_title>Retrospective Validation for Predictive Biomarkers in Stage II/III Gastric Cancer for Adjuvant Chemotherapy With S-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iwate Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iwate Medical University</source>
  <oversight_info>
    <authority>Japan: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adjuvant chemotherapy followed by curative gastrectomy for Stage II/III gastric cancer has
      improved disease free time and survival. However, there are still considerable number of
      patients experience relapse even after adjuvant chemotherapy. In an attempt to select
      patients who really benefit the postoperative adjuvant chemotherapy, we have identified
      potential biomarkers (NF-kappaB/JNK) from cell line panel screening followed by
      immunohistochemical validation. In the present study, we further validate the significance
      of the biomarkers in a larger set of clinical samples to see if chemotherapeutic response
      can be determined immediately after surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Biomarker positive</arm_group_label>
    <description>NF-kB(+)/JNK(-) in curatively removed specimens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biomarker negative</arm_group_label>
    <description>NF-kB(-)/JNK(+) in curatively removed specimens</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Archived paraffin blocks
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This is a retrospective study. Data analyses are based on archived record and materials of
        gastric cancer patients whose treatment was curative surgery followed by adjuvant
        chemotherapy with S-1.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed gastric cancer.

          -  Operated before November 2009.

          -  Stage Ib/II(except for T1, T3N0)/III.

          -  Received postoperative (R0) adjuvant chemotherapy (S-1).

          -  Not received postoperative (R0) adjuvant chemotherapy (surgery alone).

          -  Signed informed consent to provide paraffin embedded tissue of removed specimens.

        Exclusion Criteria:

          -  With advanced neoplastic lesions other than gastric cancer.

          -  Paraffin embedded tissue is not available.

          -  Unknown S-1 treatment condition.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Satoshi S Nishizuka, MD, PhD</last_name>
    <phone>+81-19-651-5111</phone>
    <phone_ext>8290</phone_ext>
    <email>snishizu@iwate-med.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Iwate Medical University School of Medicine</name>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satoshi S Nishizuka, MD, PhD</last_name>
      <phone>+81-19-651-5111</phone>
      <phone_ext>8290</phone_ext>
      <email>snishizu@iwate-med.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Satoshi S Nishizuka, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Ishida K, Nishizuka SS, Chiba T, Ikeda M, Kume K, Endo F, Katagiri H, Matsuo T, Noda H, Iwaya T, Yamada N, Fujiwara H, Takahashi M, Itabashi T, Uesugi N, Maesawa C, Tamura G, Sugai T, Otsuka K, Koeda K, Wakabayashi G. Molecular marker identification for relapse prediction in 5-FU-based adjuvant chemotherapy in gastric and colorectal cancers. PLoS One. 2012;7(8):e43236. doi: 10.1371/journal.pone.0043236. Epub 2012 Aug 14.</citation>
    <PMID>22905237</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 19, 2013</lastchanged_date>
  <firstreceived_date>July 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Iwate Medical University</investigator_affiliation>
    <investigator_full_name>Satoshi Nishizuka</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Gastric caner, adjuvant chemotherapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
